BRAF and melanoma: In contrast, apparently, with these observations, Das Thakur et al. demonstrated that some vemurafenib-resistant melanoma cell lines expressing BRAF alternative splicing variants or amplified BRAF may become drug dependent for their proliferation, and that cessation of vemurafenib exposure may lead to regression of these tumors.